



MANUSCRIPT ID: BTS0826012

STIMULI-RESPONSIVE MULTIFUNCTIONAL NANOCARRIERS FOR ON-DEMAND DRUG RELEASE: BRIDGING SMART MATERIAL DESIGN WITH CLINICAL TRANSLATION

Nukala Vedavathi, Pabbiniddi Veeralakshmi, Vanasala lakshmi jyothsna, Yerramsetti Prasanth
Department of Pharmaceutics, SPST, JNTUK, Kakinada, Andhra Pradesh, INDIA

Corresponding Author Mail Id: pabbiniddiveeralakshmi@gmail.com

Received: 10 July 2026 | **Revised & Accepted:** 25 July 2026

Keywords: Stimuli-responsive, nanocarriers, targeted drug delivery, multifunctional design, theranostics, personalized medicine.

ABSTRACT

Stimuli-responsive multifunctional nanocarriers are advanced, intelligent drug delivery systems specifically designed to release their therapeutic contents in reaction to certain internal triggers like pH levels, enzymes, or redox conditions, as well as external factors such as temperature, light, or magnetic fields, enabling targeted and immediate drug release. By incorporating responsive materials, ligands, and imaging agents, these nanocarriers facilitate accurate spatial and temporal regulation of drug distribution in the body, notably improving therapeutic effectiveness while reducing off-target impacts and overall toxicity. The clinical promise of these nanocarriers is particularly noticeable in the management of cancer, inflammatory conditions, and neurological illnesses, where their multifunctional design facilitates both therapeutic and diagnostic applications (theranostics). As initiatives progress to address issues related to biocompatibility, large-scale production, and regulatory clearance, these nanocarriers are set to transform personalized medicine by enabling more precise, effective, and safer drug delivery.

INTRODUCTION

Stimuli-responsive multifunctional nanocarriers have become a groundbreaking approach in targeted and controlled drug delivery, providing unmatched accuracy in therapeutic interventions.[1] These sophisticated nanoplatforms are designed to respond to internal physiological signals (like pH, enzyme levels, redox potential, or hypoxia) or external physical factors (such as temperature, magnetic fields, light: and ultrasound) to facilitate the release of encapsulated medications at the specific site of action when needed[5]. The core concept is based on incorporating smart materials that change their physicochemical properties in reaction to certain stimuli,

allowing for controlled drug release in both space and time while minimizing systemic toxicity and improving patient adherence[1][4].

In the past few years, the creation of multifunctional nanocarriers has connected material engineering with clinical application, integrating diagnostic, therapeutic, and targeting components into one nanosystem. Various types of nanocarriers, such as polymeric nanoparticles, liposomes, dendrimers, micelles, and inorganic nanosystems, have been thoroughly investigated for their reactions to stimuli.[6] Incorporating targeting ligands-like antibodies, peptides, or aptamers-improves selective concentration in affected tissues by taking



MANUSCRIPT ID: BTS0826012

advantage of pathological characteristics, such as acidic environments in tumors or enzymes that are produced in excess, to activate the release of drugs. Furthermore, the use of theranostic agents together allows for concurrent imaging and treatment, pushing the field closer to precision and personalized medicine[2].

The clinical use of these multifunctional carriers is growing quickly, especially in the areas of cancer treatment, neurological conditions, inflammatory diseases, and antimicrobial therapies. For instance, nanocarriers that are sensitive to pH and redox conditions have demonstrated exceptional ability to control the release of anticancer drugs in acidic tumor environments or in areas with high glutathione levels[2]. Systems that respond to dual or multiple stimuli can improve therapeutic outcomes by providing

synergistic control using both internal and external triggers. However, obstacles remain regarding large-scale production, biocompatibility, reproducibility, and meeting safety standards for regulatory approval.[3](Pabbiniddi & Kotra, 2024)

The ongoing research path emphasizes transforming designs developed in laboratories into products suitable for clinical use by incorporating biocompatible materials, enhancing pharmacokinetic characteristics, and refining the equilibrium between structural intricacy and functional effectiveness. In this context, stimuli-responsive multifunctional nanocarriers exemplify a merging of advanced material science and pharmaceutical applications, created to deliver targeted, efficient, and safe treatments as needed-connecting the gap between innovative laboratory developments and clinical practice. [12]




Fig. 1: The nanocarriers that respond to stimuli are designed for delivering drugs to tumors, facilitating precision imaging, effective treatment, and theranostic applications.[7][11] These



MANUSCRIPT ID: BTS0826012

nanocarriers can gather in and infiltrate tumors while specifically targeting cancer cells to perform various functions by reacting to both external and internal stimuli.[2][38]

NANOCARRIERS IN STIMULI-RESPONSIVE ON-DEMAND DRUG DELIVERY:

Nanocarriers are tiny delivery systems designed to transport therapeutic agents effectively to targeted biological areas. In the realm of stimuli-responsive drug delivery, these nanocarriers are constructed from intelligent materials that respond to specific internal or external stimuli, allowing for precise, on-demand drug release at the site of interest. This category of nanosystems encompasses a variety of platforms such as polymeric nanoparticles, liposomes, dendrimers, micelles, mesoporous silica nanoparticles, and inorganic nanoparticles, each presenting distinct benefits for stimuli responsiveness and multifunctionality.[20][34]

Smart Material Foundations and Responsive Mechanisms

Stimuli-responsive nanocarriers are sophisticated drug delivery systems

developed to utilize both internal (endogenous) and external (exogenous) physiological signals for accurate, on-demand therapeutic release.[14] Internal signals consist of variations in pH, over-expression of enzymes, redox gradients, and hypoxic conditions-frequently found in diseased tissues like tumors or inflamed areas.[2] External signals involve physical stimuli such as temperature, light, ultrasound, or magnetic fields, which can be applied to the targeted location[23]. By employing careful design, these carriers combine smart polymers, lipids, or inorganic materials that undergo physicochemical alterations (including structural changes, bond breaking, or shifts in surface charge) in reaction to the specific stimulus, thus allowing for controlled drug encapsulation and reliable release profiles.[3][8]




Fig. 2: Types of stimuli (external and internal)

Design Strategies and Multifunctionality

Modern stimuli-responsive nanocarriers are inherently multifunctional. Key carriers consist of polymeric nanoparticles, liposomes, dendrimers, micelles, and inorganic nanostructures. Their surfaces can be modified with targeting ligands (such as antibodies, peptides, or aptamers)

to ensure targeted delivery to disease locations. [15]The co-encapsulation of imaging agents allows for real-time observation and theranostics-integrating diagnosis and treatment. The addition of "stealth" materials like polyethylene glycol (PEG) increases circulation duration and reduces immune system recognition, while



MANUSCRIPT ID: BTS0826012

the versatility of these platforms permits dual- or multi-stimuli responsiveness, providing synergistic control to further

improve site-specificity and drug delivery effectiveness.[20]




Fig 3: Drug Delivery of Nano Carriers

Multifunctional Drug Delivery Systems (MDDS)

The advancement of drug carriers designed to specifically target diseased regions arose from the necessity to address various drug limitations, such as cytotoxic effects, immunogenic responses, brief circulation periods, uncontrolled biodistribution, and the inability to target specific tissues. In recent years, notable progress in nanobiotechnology has facilitated the creation of Multi-Drug Delivery Systems (MDDS), which serve dual purposes of diagnosis and therapy through a single medical device.[23] This innovative device can perform bio-imaging functions while also enhancing the therapeutic effectiveness of existing medications. The MDDS described in the literature can exhibit diverse morphologies and sizes, utilizing a range of materials including natural and synthetic polymers, lipids, as well as other organic and inorganic substances.[2][35](Prasanth et al., 2023)

Polymeric nanostructures are the most commonly utilized carriers in drug delivery systems, owing to their numerous benefits, such as versatility in fabrication, the ability to control size and shape, high encapsulation efficiency, and the

convenience of surface functionalization with various targeting agents, including peptides, proteins, and antibodies[13]. Additionally, applying stealth materials like poly(ethylene glycol) (PEG) to these nanostructures enhances their circulation duration within the body. When paired with their targeting capabilities, this makes them ideal for selectively delivering a variety of therapeutic agents, such as drugs, enzymes, proteins, RNA, and DNA to specific diseased tissues. The most frequently employed polymeric nanostructures include nanoparticles, nanocapsules, dendrimers, nanospheres, spherical and worm-like micelles, nanotubes, and hydrogels.[4](G & P, 2020)

MECHANISMS OF STIMULUS-TRIGGERED DRUG RELEASE:

PH-sensitive carriers take advantage of the acidic Microenvironments present in tumors or specific intracellular compartments to initiate degradation of the material or changes in membrane permeability, allowing selective release of drugs at the site of disease.[21]

Redox-sensitive nanocarriers react to the elevated levels of glutathione found within cells or tumors, employing disulfide bond



cleavage to achieve controlled drug release.[10]

Enzyme-sensitive systems leverage the overabundance of certain enzymes (such as matrix metalloproteinases in tumors) to break down carrier matrices, thereby freeing the payloads.[23]

Externally triggered systems-including magnetic, thermal, light, or ultrasound-responsive nanocarriers-allow for noninvasive, remote-controlled release patterns, offering precise timing and minimizing risks to healthy tissues.[3][17]

ADVANTAGES

Targeted and Controlled Drug Release:

These nanocarriers are capable of accurately delivering drugs in response to specific internal triggers (like pH levels, enzymes, or redox conditions) or external influences (such as temperature, light, or magnetic fields). This guarantees delivery to the intended site while reducing systemic side effects, thereby enhancing therapeutic effectiveness, particularly in cases of cancer and inflammatory conditions.[16]

Multifunctionality: The combination of targeting ligands, imaging agents, and responsiveness to various stimuli enables integrated therapeutic and diagnostic (theranostic) uses, facilitating real-time observation of drug release and the progression of diseases.[24]

Enhanced Drug Stability and Solubility:

The encapsulation of drugs within nanocarriers safeguards them against premature degradation and boosts their solubility, extending circulation time and bioavailability.[18][37]

Overcoming Biological Barriers:

Stimuli-responsive nanocarriers can be designed to navigate challenging biological barriers such as the blood-brain barrier or the tumor microenvironment,

thereby improving drug accumulation and cellular uptake.(Lakshmi et al., 2019)

Reduction of Multidrug Resistance: By releasing drugs specifically at sites of disease and supporting combination therapies, these nanocarriers may assist in overcoming the drug resistance mechanisms present in cancer cells.[35]

DISADVANTAGES

The intricacies associated with design and synthesis:

The multifunctional nature and ability to respond to stimuli introduce additional complexity in the creation of nanocarriers, necessitating precise control over material characteristics and functionalization, which may hinder scalability and reproducibility.[14][26]

Possible Immunogenic Reactions and Toxicity:

Even though biocompatible materials are employed, concerns regarding long-term safety and potential immune responses must be thoroughly assessed prior to clinical application.[11][27]

Fluctuations in Stimuli Levels: Internal stimuli (such as pH and enzyme concentrations) can differ among patients or across various disease stages, which may result in unpredictable drug release profiles and therapeutic results. [19][20]

Regulatory and Manufacturing

Obstacles: Complex nanocarriers encounter significant regulatory oversight, and achieving consistency in large-scale production from batch to batch remains a considerable challenge.[38]

Restricted Penetration in Diverse

Tumors: In spite of targeting capabilities and responsiveness to stimuli, the varied nature of tumor environments may hinder the even distribution of nanocarriers and the release of drugs throughout the tumor tissue[25]



CLINICAL AND THERAPEUTIC APPLICATIONS

The principal advantage of these nanocarriers lies in their ability to achieve high local drug concentrations, reduce systemic toxicity, and address obstacles like multidrug resistance, particularly in oncology.[22]

Cancer: Enhanced antitumor effects and the ability to overcome resistance are achieved through targeted, stimuli-triggered release in the tumor microenvironment.[28]

Inflammatory and Autoimmune Diseases: Release that responds to inflamed areas minimizes off-target consequences[.28]

Neurological Disorders: The capability to penetrate barriers such as the blood-brain barrier (BBB), with controlled release tailored to neurological microenvironments.[22]

Theranostics: The concurrent use of imaging and treatment (for example, using MRI or fluorescent imaging agents delivered alongside therapeutics) allows for real-time tracking of delivery and effectiveness.[36]

CHALLENGES AND FUTURE PERSPECTIVES

Although laboratory and preclinical findings are encouraging, multiple obstacles need to be overcome for effective clinical application:[32]

Standardization and Scalability: The establishment of large-scale, standardized manufacturing processes is crucial to guarantee consistency between batches.

Regulatory Challenges and Biocompatibility: Thorough assessment of toxicity, immunogenicity, and long-term behavior is vital for gaining regulatory approval.[31]

MANUSCRIPT ID: BTS0826012

Complexities of Disease Variability: A deeper understanding of individual patients' pathological characteristics can facilitate the creation of more tailored nanocarriers.[31][30]

Future research is focusing on integrating multiplexed functionalities, optimizing material properties for human use, and streamlining regulatory pathways. The interdisciplinary nature of these efforts—merging pharmaceutical sciences, material engineering, and clinical medicine—holds promise for the continued advancement and eventual routine clinical use of these smart systems for precision medicine.[33]

The collaborative nature of these Initiatives-integrating pharmaceutical sciences, materials engineering, and clinical medicine -offers promising potential for the ongoing development and eventual routine application of these advanced systems in precision medicine.(Chowdary, 2018)

CONCLUSION

Stimuli-responsive multifunctional nanocarriers mark a major progression in targeted drug delivery by integrating intelligent material design with real-world clinical applications for the on-demand release of therapeutics at specific locations[9]. These nanocarriers utilize both natural stimuli such as changes in pH, enzyme activity, redox gradients, and hypoxic conditions, along with external stimuli like temperature variations, light exposure, magnetic fields, and ultrasound to initiate accurate drug release exclusively at the intended site[26]e. Their multifunctional nature-incorporating targeting ligands, imaging agents for diagnostics, and mechanisms for controlled release-facilitates improved therapeutic effectiveness while reducing systemic toxicity, and also promotes theranostic



MANUSCRIPT ID: BTS0826012

applications, thereby enhancing precision medicine[14]. The capacity of these nanocarriers to navigate biological barriers, diminish off-target impacts, and tackle multidrug resistance highlights their great potential for clinical application, particularly in the fields of cancer, inflammatory conditions, and neurological disorders. Nevertheless, obstacles persist in increasing production capacity, guaranteeing biocompatibility, ensuring reproducibility, and maneuvering through regulatory frameworks. Ongoing

interdisciplinary research aimed at enhancing the biocompatibility of materials, their responsiveness, and manufacturing techniques is crucial for unlocking the complete clinical potential of these advanced delivery systems.[29] In summary, stimuli-responsive multifunctional nanocarriers occupy a pivotal position in personalized medicine and are ready to transform therapeutic approaches by bridging the divide between cutting-edge materials science and applicable clinical solutions.[31]

Stimulus Type	Example Nanocarrier Designs	Triggered Application
pH	Polymeric micelles, liposomes	Tumor-targeted chemotherapeutic release
Enzyme	Dendrimer-based degradable formulations	Release in cancer/inflamed microenvironments
Redox	Disulfide-linked nanoparticles	Intracellular anticancer drug release
Temperature	Thermosensitive liposomes/micelles	Hyperthermia-induced local release
Magnetic Field	Magnetic nanoparticles	Targeting, imaging, remote-triggered release
Light/Ultrasound	Photosensitive/liposomes	Precise, site-specific drug activation

REFERENCES

1. Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. *Theranostics*. 2020.
2. Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. *Expert Opin Drug Deliv*. 2020.
3. Sun Y, Davis E. Nanoplatfroms for targeted stimuli-responsive drug delivery. *Nanomaterials*. 2021.
4. Zhang Q, et al. Stimuli-responsive gene delivery nanocarriers for cancer therapy. *Nano-Micro Lett*. 2023.
5. Parvin N, et al. Biodegradable and stimuli-responsive nanomaterials for autoimmune diseases. *J Funct Biomater*. 2025.
6. Li W, et al. Stimuli-responsive nanocarriers for lung diseases. *Front Bioeng Biotechnol*. 2025.
7. ScienceDirect Review. Stimuli-responsive smart nanocarriers for skin drug delivery. 2026.
8. Zhou M, et al. Application of stimuli-responsive nanocarriers for targeted drug delivery. *Curr Top Med Chem*. 2017.



MANUSCRIPT ID: BTS0826012

9. Elsevier Book Chapter. Stimuli-responsive nanocarriers for drug delivery. 2020.
10. Shi J, Kantoff PW, Wooster R, Farokhzad OC. *Cancer nanomedicine: progress, challenges and opportunities*. *Nat Rev Cancer*. 2017;17:20–37. doi: 10.1038/nrc.2016.108.
11. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. *Theranostics*. 2014;4:660–77. doi: 10.7150/thno.8698.
12. Liu D, Yang F, Xiong F, Gu N. *The smart drug delivery system and its clinical potential*. *Theranostics*. 2016;6:1306–23. doi: 10.7150/thno.14858.
13. Li C, Zhang Y, Li Z, Mei E, Lin J, Li F. et al. Light-responsive biodegradable nanorattles for cancer theranostics. *Adv Mater*. 2018;30:1706150. doi: 10.1002/adma.201706150.
14. Hu QY, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. *Nanoscale*. 2014;6:12273–86. doi: 10.1039/c4nr04249b.
15. Xin X, Teng C, Du X, Lv Y, Xiao Q, Wu Y. et al. Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route. *Theranostics*. 2018;8:3474–89. doi: 10.7150/thno.23804.
16. Cai H, Wang X, Zhang H, Sun L, Pan D, Gong Q. et al. Enzyme-sensitive biodegradable and multifunctional polymeric conjugate as theranostic nanomedicine. *Appl Mater Today*. 2018;11:207–18.
17. Raza A, Rasheed T, Nabeel F, et al. Endogenous and exogenous stimuli-responsive drug delivery systems for programmed site-specific release. *Molecules*. 2019. March 21;24:6.
18. Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. *J Control Release*. 2015. December;10 (219):205–214.
19. de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. *Adv Drug Deliv Rev*. 2012. August;64 (11):967–978.
20. Gawai AY, Kadu SS, Patil RJ, et al. Stimuli-responsive nanocarriers for site-specific drug delivery system. *Asian J Pharm Res Dev*. 2025;13(2):100–106. doi:10.22270/ajprd.v13i2.1547.
21. Wang T, Wu C, Hu Y, Zhang Y, Ma J. Stimuli-responsive nanocarrier delivery systems for platinum-based anticancer drugs. *RSC Adv*. 2023;13:12888–12906.
22. Zhao X, Liu Y, Li S, et al. Stimuli-responsive nanocarriers for therapeutic applications. *Front Bioeng Biotechnol*. 2021;9:675844.
23. Majumder J, Taratula O, et al. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic drug delivery applications. *Expert Opin Drug Deliv*. 2023;20(5):611–630.
24. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the advancement of cancer therapy. *Adv Drug Deliv Rev*. 2012;64(9):866–884.
25. Ganta S, Devalapally H, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. *J Control Release*. 2008;126(3):187–204.
26. Parra-Nieto J, Hernández-Gil J, Khairnar K, et al. Stimuli-responsive nanocarriers as active enhancers of immunotherapeutic efficacy. *Adv Mater Interfaces*. 2024;11(4):2400343.
27. Mura, S., Nicolas, J., and Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nat. Mater*. 12, 991–1003. doi:10.1038/nmat3776.
28. Srinivasan, M., Rajabi, M., and Mousa, S. A. (2015). Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. *Nanomaterials*



MANUSCRIPT ID: BTS0826012

- (Basel) 5, 1690–1703. doi:10.3390/nano5041690.
29. Bose, R. J., Lee, S. H., and Park, H. (2016). Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments. *Drug Discov. Today* 21, 1303–1312. doi:10.1016/j.drudis.2016.06.005.
30. Lu, Y., Aimetti, A. A., Langer, R., and Gu, Z. (2016). Bioresponsive materials. *Nat. Rev. Mater.* 2, 16075. doi:10.1038/natrevmats.2016.75.
31. Theato, P., Sumerlin, B. S., O'Reilly, R. K., and Epps, T. H. III (2013). Stimuli responsive materials. *Chem. Soc. Rev.* 42, 7055–7056. doi:10.1039/c3cs90057f.
32. Luk, B. T., and Zhang, L. (2015). Cell membrane-camouflaged nanoparticles for drug delivery. *J. Control Release* 220(Pt B), 600–607. doi:10.1016/j.jconrel.2015.07.019.
33. Krishnamurthy, S., Gnanasammandhan, M. K., Xie, C., Huang, K., Cui, M. Y., and Chan, J. M. (2016). Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. *Nanoscale* 8, 6981–6985. doi:10.1039/c5nr07588b.
34. Chen HB, Gu ZJ, An HW, Chen CY, Chen J, Cui R. et al. Precise nanomedicine for intelligent therapy of cancer. *Sci China Chem.* 2018;61:1503–52.
35. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. *Nat Nanotechnol.* 2019;14:1007–17. doi: 10.1038/s41565-019-0567-y.
36. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. *Theranostics.* 2014;4:660–77. doi: 10.7150/thno.8698.
37. Wang S, Huang P, Chen X. Stimuli-responsive programmed specific targeting in nanomedicine. *ACS Nano.* 2016;10:2991–4. doi: 10.1021/acsnano.6b00870.
38. Huang P, Wang G, Su Y, Zhou Y, Huang W, Zhang R. et al. Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment. *Theranostics.* 2019;9:5755–68. doi: 10.7150/thno.36163.